Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.73 |
| ▸ | PPARG | P37231 | 13/20 | 0.70 |
| ▸ | PPARD | Q03181 | 9/20 | 0.70 |
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455247 | 1.00 | PPARA (0.73) | PPARAPPARGPPARDLDHA | |
| SCHEMBL7617610 | 0.98 | PPARA (0.72) | PPARAPPARGPPARDLDHA | |
| SCHEMBL7617605 | 0.88 | PPARA (0.57) | PPARAPPARGPPARDLDHA | |
| SCHEMBL27674855 | 0.86 | PPARA (0.81) | PPARAPPARGPPARD | |
| SCHEMBL4462278 | 0.85 | LDHA (0.71) | PPARAPPARGPPARDLDHA | |
| SCHEMBL4462284 | 0.85 | LDHA (0.71) | PPARAPPARGPPARDLDHA | |
| SCHEMBL27654986 | 0.84 | PPARA (0.85) | PPARAPPARGPPARD | |
| SCHEMBL6420355 | 0.84 | PPARD (1.00) | PPARAPPARGPPARD | |
| SCHEMBL17680422 | 0.83 | PPARA (0.68) | PPARAPPARGPPARD | |
| SCHEMBL5543269 | 0.83 | PPARA (0.72) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7002037-B2 | Process for the preparation on enantiomerically enriched compounds | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | claimed |
| EP-1237838-B1 | NEW PROCESS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | claimed |
| US-9550719-B2 | Process for the preparation of 3-aryl-2-hydroxy propanoic acid compounds | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-01-24 | — | — | US | disclosed |
| US-9550719-B2 | Process for the preparation of 3-aryl-2-hydroxy propanoic acid compounds | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-01-24 | — | — | US | disclosed |
| US-20160102042-A1 | A PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID COMPOUNDS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-04-14 | — | — | US | disclosed |
| US-20160102042-A1 | A PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID COMPOUNDS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-04-14 | — | — | US | disclosed |
| US-20090082441-A1 | DEUTERIUM-ENRICHED TESAGLITAZAR | PROTIA, LLC (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082441-A1 | DEUTERIUM-ENRICHED TESAGLITAZAR | PROTIA, LLC (US) | 2009-03-26 | — | — | US | disclosed |
| US-20060069283-A1 | New process | ANDERSSON KJELL | 2006-03-30 | — | — | US | disclosed |
| US-7002037-B2 | Process for the preparation on enantiomerically enriched compounds | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1237838-B1 | NEW PROCESS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1237855-B1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030139474-A1 | Resolution of enantiomorphs | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| US-6531622-B1 | Insulin Resistance Syndrome; metabolic disorders; crystallization | ASTRAZENECA AB (SE) | 2003-03-11 | — | — | US | disclosed |
| EP-1237855-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1237838-A1 | NEW PROCESS | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040159-A1 | NEW PROCESS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139474-A1 | Resolution of enantiomorphs | GPR119, INSR, IRS1 | PPARA 78/4885PPARG 296/4885PPARD 88/4885 |
| US-20090082441-A1 | DEUTERIUM-ENRICHED TESAGLITAZAR | GCGR, GLP1R, GIPR | PPARA 854/4885PPARG 215/4885PPARD 318/4885 |
| US-20160102042-A1 | A PROCESS FOR THE PREPARATION OF 3-ARYL-2-HYDROXY PROPANOIC ACID COMPOUNDS | P4HA1, HCAR1, HPD | PPARA 206/4885PPARG 525/4885PPARD 538/4885 |
| US-20060069283-A1 | New process | GPR119, IRS1, INSR | PPARA 124/4885PPARG 410/4885PPARD 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.